[go: up one dir, main page]

SE0002189D0 - New method and assay - Google Patents

New method and assay

Info

Publication number
SE0002189D0
SE0002189D0 SE0002189A SE0002189A SE0002189D0 SE 0002189 D0 SE0002189 D0 SE 0002189D0 SE 0002189 A SE0002189 A SE 0002189A SE 0002189 A SE0002189 A SE 0002189A SE 0002189 D0 SE0002189 D0 SE 0002189D0
Authority
SE
Sweden
Prior art keywords
irs
assay
sequences
diabetes
markers
Prior art date
Application number
SE0002189A
Other languages
English (en)
Inventor
Ulf Smith
Original Assignee
Metcon Medicin Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metcon Medicin Ab filed Critical Metcon Medicin Ab
Priority to SE0002189A priority Critical patent/SE0002189D0/sv
Publication of SE0002189D0 publication Critical patent/SE0002189D0/sv
Priority to AU2001274722A priority patent/AU2001274722A1/en
Priority to PCT/SE2001/001308 priority patent/WO2001094410A1/en
Priority to US09/875,945 priority patent/US6835819B2/en
Priority to EP01941363A priority patent/EP1287030A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SE0002189A 2000-06-08 2000-06-09 New method and assay SE0002189D0 (sv)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE0002189A SE0002189D0 (sv) 2000-06-09 2000-06-09 New method and assay
AU2001274722A AU2001274722A1 (en) 2000-06-08 2001-06-08 Insulin regulated substance (irs-2) induced by pioglitazone, assay and use thereof
PCT/SE2001/001308 WO2001094410A1 (en) 2000-06-08 2001-06-08 Insulin regulated substance (irs-2) induced by pioglitazone, assay and use thereof
US09/875,945 US6835819B2 (en) 2000-06-08 2001-06-08 Sequences and their use
EP01941363A EP1287030A1 (en) 2000-06-08 2001-06-08 Insulin regulated substance (irs-2) induced by pioglitazone, assay and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0002189A SE0002189D0 (sv) 2000-06-09 2000-06-09 New method and assay

Publications (1)

Publication Number Publication Date
SE0002189D0 true SE0002189D0 (sv) 2000-06-09

Family

ID=20280058

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0002189A SE0002189D0 (sv) 2000-06-08 2000-06-09 New method and assay

Country Status (2)

Country Link
US (1) US6835819B2 (sv)
SE (1) SE0002189D0 (sv)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2515518A1 (en) * 2003-01-02 2004-07-22 Gerard M. Housey Irs modulators
JP5903735B2 (ja) * 2009-05-11 2016-04-13 バーグ エルエルシー エピメタボリックシフター（コエンザイムｑ１０）を使用した疾患の処置方法
KR101703695B1 (ko) * 2009-05-22 2017-02-08 큐알엔에이, 인크. 전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
EP2694463B8 (en) 2011-04-04 2019-10-09 Berg LLC Treating central nervous system tumors with coenzyme q10
CN105338973A (zh) 2013-04-08 2016-02-17 博格有限责任公司 使用辅酶q10联合疗法治疗癌症
ES2825083T3 (es) 2013-09-04 2021-05-14 Berg Llc Métodos de tratamiento contra el cáncer mediante infusión continua de coenzima Q10
US20170189350A1 (en) 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578444A (en) 1991-06-27 1996-11-26 Genelabs Technologies, Inc. Sequence-directed DNA-binding molecules compositions and methods
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5858701A (en) 1994-10-03 1999-01-12 Joslin Diabetes Center, Inc. DNA encoding an insulin receptor substrate
AU7181198A (en) 1996-11-13 1998-06-03 Receptron Corporation Assays for non-insulin dependent diabetes
WO1998056909A2 (en) 1997-06-11 1998-12-17 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them

Also Published As

Publication number Publication date
US6835819B2 (en) 2004-12-28
US20020098169A1 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
Tenchov et al. Aging hallmarks and progression and age-related diseases: a landscape view of research advancement
Ivanov et al. G-quadruplex structures contribute to the neuroprotective effects of angiogenin-induced tRNA fragments
Sbodio et al. Transcriptional control of amino acid homeostasis is disrupted in Huntington’s disease
Haeberle et al. Molecular profiling reveals synaptic release machinery in Merkel cells
Ye et al. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease
Tomasek et al. Gelatinase A activation is regulated by the organization of the polymerized actin cytoskeleton
Lewis et al. Pathophysiologically based treatment interventions in schizophrenia
Vacca et al. Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A
Shih et al. Cranial muscle defects of Pitx2 mutants result from specification defects in the first branchial arch
Kitami et al. A chemical screen probing the relationship between mitochondrial content and cell size
DK1666052T3 (da) Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer
Colzato et al. Effects of l-Tyrosine on working memory and inhibitory control are determined by DRD2 genotypes: A randomized controlled trial
Jermakowicz et al. The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion
Nakao et al. Proteoglycan expression is influenced by mechanical load in TMJ discs
Rabie et al. Forward mandibular positioning up-regulates SOX9 and type II collagen expression in the glenoid fossa
Popescu et al. Challenges in anti‐aging medicine–trends in biomarker discovery and therapeutic interventions for a healthy lifespan
SE0002189D0 (sv) New method and assay
Stowe et al. Cellular senescence impairs tendon extracellular matrix remodeling in response to mechanical unloading
BRPI0406680A (pt) Métodos para selecionar um animal para ter propriedades desejadas genotìpicas ou fenotìpicas em potencial, para modular a trascrição de mrna de um gene igf2 em uma célula ou organismo provido com referido gene e para identificar um composto, composto, composição farmacêutica, e, uso de um composto
Walker et al. Cerebral and skeletal muscle feed artery vasoconstrictor responses in a mouse model with greater large elastic artery stiffness
Mosole et al. Effects of electrical stimulation on skeletal muscle of old sedentary people
Lin Regulation of proteolytic cleavage of brain-derived neurotrophic factor precursor by antidepressants in human neuroblastoma cells
WO2006091964A8 (en) Regulators of protein misfolding and aggregation and methods of using the same
Haws et al. Cutaneous findings in Bardet‐Biedl syndrome
NO20021147D0 (no) Polymorfismer i det humane hPXR-genet og deres anvendelse i diagnostiske og terapeutiske applikasjoner